Skip to content

Adverum Biotechnologies, Inc.

CIK 0001501756

← back to feed
Revenue (TTM)
$1M
0.0% YoY Q3 Nov 2025
Net Income (TTM)
−$176.21M
−304.7% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$8.17
−327.1% YoY Q3 Nov 2025
Gross Margin
90.0%
Q3 Nov 2025
Operating Margin
-18,053.7%
Q3 Nov 2025
Net Margin
-17,621.3%
Q3 Nov 2025
Free Cash Flow (TTM)
−$122.13M
Q3 Nov 2025
Cash
$26.06M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
22.08M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings